financial results

The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests. 

The company said revenues from sales of its software services rose more than 250 percent during the quarter.

Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.

The firm reported $6.3 million in third quarter revenues compared to $2.2 million in the year ago period, but fell short of the consensus Wall Street estimate of $7.5 million.

Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.

Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.   

The revenue increase was driven by increased sales of its Afirma gene classifier thyroid test, as well as improved predictability of payments.

The firm said it is on track for solid future growth based on the expectation for new product approvals and continued strength in the CareFusion product portfolio. 

Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.

The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.